Due diligence is the structured review an investor or acquirer conducts before closing a transaction. MedTech diligence spans regulatory (510(k) history, warning letters, recalls), clinical (trial protocols, data integrity), IP (freedom-to-operate, patent prosecution), quality (QMS, FDA inspections), commercial (pipeline, contracts), and financial.

Why it matters

Regulatory and quality DD findings frequently kill or reprice MedTech deals. A clean inspection history and well-organized DHF/DMR speed transactions materially.

Common pitfalls

•Confusing the legal and financial aspects of due diligence with the technical regulatory and quality assessments.
•Failing to involve regulatory, quality, and cybersecurity experts early in the due diligence process, leading to overlooked critical issues.
•Underestimating the impact of unresolved regulatory actions, such as Warning Letters or 483s, on deal valuation and post-acquisition integration.
•Not verifying the accuracy and completeness of submitted regulatory documentation, like 510(k) clearances or technical files.
•Ignoring cybersecurity risks and past breaches during due diligence, which can lead to significant post-acquisition liabilities and reputational damage.

Sources

PitchBook - MedTech Coverage · PitchBook
NVCA Model Documents · NVCA
SEC capital-raising glossary: due diligence · U.S. Securities and Exchange Commission

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.